PMA device
Shield
Guardant Health, Inc. · System, Colorectal Neoplasia, Dna Methylation And Hemoglobin Detection (PHP, Class III) · First FDA decision Jul 26, 2024, newest Jul 22, 2026Colorectal cancer and polyps
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
3
PMA pathway
Device trials
145
Naming "Shield"
MAUDE reports
4,809
Brand "Shield", since 2015
PubMed studies
14,799
Mentioning "Shield"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Shield
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 3 of 3 decisions filed under this name.
- ShieldPMA supplement
P230009-S010 · Decided Jul 22, 2026 · 250 days after receipt · Normal 180 Day Track
Device type: System, colorectal neoplasia, DNA methylation and hemoglobin detection (PHP) · Laboratory Medicine & Pathology
2 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- MolDX: Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia, and NeoplasiaLocal determinationIn effectL39276CGS Administrators, LLCUpdated Feb 13, 2026
- MolDX: Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia, and NeoplasiaLocal determinationIn effectL39262Noridian Healthcare Solutions, LLCUpdated Jan 12, 2026
- MolDX: Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia, and NeoplasiaLocal determinationIn effectL39256Palmetto GBAUpdated Mar 4, 2025
- MolDX: Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia, and NeoplasiaLocal determinationIn effectL39356WPS Insurance CorporationUpdated Feb 20, 2025
Clinical trials
Device studies on ClinicalTrials.gov that name "Shield", any status and sponsor, newest update first.
- The Vanguard Study: Testing a New Way to Screen for CancerPivotal-lookingRecruiting
National Cancer Institute (NCI)NIH
NCT06995898 · 24,000 participants (planned) · Start Jun 18, 2025 · Primary completion Jan 31, 2029
Device: Device Usage · For: Bladder Carcinoma; Breast Carcinoma; Colorectal Carcinoma and 8 more
Sites: Pleasanton, California; San Diego, California; Cheyenne Wells, Colorado · 49 sites in all
144 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Shield", and for the whole product code for context.
This brand
4,809 reports: 3,986 malfunction, 708 injury, 113 death
Whole product code PHP
33 reports: 20 malfunction, 10 injury, 1 death
Newest reports for this brand
- PIPELINE FLEX W/SHIELD TECHNOLOGYMalfunction
Micro Therapeutics, Inc. dba ev3
2029214-2026-02136 · Received Oct 29, 2026 · Event dated Oct 26, 2026
Device type: Intracranial Aneurysm Flow Diverter (OUT)
Device problem as coded: Activation Failure
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
4 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Shield"[tiab]. The summary above synthesizes these.
- Understanding Shield Laws.
Cohen DS, Donley G, Rebouché R, et al. · J Law Med Ethics · 2023
- Shield synthesis.
Könighofer B, Alshiekh M, Bloem R, et al. · Form Methods Syst Des · 2017
- Effectiveness of the socket shield technique in dental implant: A systematic review.
Ogawa T, Sitalaksmi RM, Miyashita M, et al. · J Prosthodont Res · 2022Systematic Review
- Abortion Shield Laws.
Cohen DS, Donley G, Rebouché R · NEJM Evid · 2023Review
- Abortion Shield Laws in Action.
Cohen DS, Donley G, Rebouché R · JAMA Intern Med · 2025
- Nipple Shield Made from a Thermoplastic with Aluminum Properties.
Soyano H, Matsumine H · Plast Reconstr Surg Glob Open · 2023
- The Dalkon Shield.
FDA Consum · 1975
- SHIELD: Skull-shaped hemispheric implants enabling large-scale electrophysiology datasets in the mouse brain.
Bennett C, Ouellette B, Ramirez TK, et al. · Neuron · 2024Research Support, Non-U.S. Gov't
- VA SHIELD: A Biorepository for Veterans and the Nation.
Epstein L, Shive C, Garcia AP, et al. · Fed Pract · 2023
- An inhaled bioadhesive hydrogel to shield non-human primates from SARS-CoV-2 infection.
Mei X, Li J, Wang Z, et al. · Nat Mater · 2023Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural
- Novel Use of Tracheostomy Shield for Emergency Tracheostomy in Covid 19 Era.
Kirti YK, Soni S, Yashveer JK, et al. · Indian J Otolaryngol Head Neck Surg · 2022
- Integrated 'Shield-Spear' Biological Patch for Fibrosis-Free Bladder Reconstruction.
Wu X, Ruan H, Zhang X, et al. · Adv Sci (Weinh) · 2025
Other devices of this type
Also filed under product code PHP.
- CologuardExact Sciences Corporation · PMA 2024
- Epi proColonNew Day Diagnostics, LLC · PMA 2016
- SimpleScreen CRCFreenome, LLC · PMA 2026
- ColoHealthNew Day Diagnostics, LLC · PMA 2025
- Multi-Target Stool DNA (mtsDNA) Test, Cologuard PlusExact Sciences Corporation · PMA 2024
- Cologuard Stool DNA-Based Colorectal Cancer Screening TestExact Sciences Corporation · PMA 2019
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.